Saturday 17 October 2026
Export RNXT’s income statement to Excel — free account
RenovoRx, Inc.
RNXT Healthcare Biotechnology
RenovoRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 million, up 2,511.6% from fiscal 2024. In the quarter to June 2026, revenue grew 115.4%, EPS grew 25.0% and free cash flow fell 27.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.15
0.04
−3.36%
Follow RNXT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
23.46 | 25.80 | 26.43 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(16.17) | (10.36) | (9.83) | (20.50) | |
P/B ratio |
5.16 | 3.41 | 5.47 | 5.76 | |
Price to Tangible BV |
5.16 | 3.41 | 5.47 | 5.76 | |
EV/Sales |
21.09 | 20.72 | 24.45 | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.51) | (2.73) | (2.50) | (3.98) | |
EV/FCF |
(3.49) | (2.73) | (2.50) | (3.97) | |
Quick Ratio |
5.29 | 6.58 | 3.65 | 5.42 | |
Current Ratio |
5.74 | 7.15 | 4.02 | 5.83 | |
Net Debt/EBITDA |
2.83 | 3.56 | 1.99 | 3.14 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.16 | 0.10 | 0.14 | 0.00 | |
Operating CF/Net income |
0.98 | 1.05 | 1.03 | 0.78 | |
Capex/Depreciation |
(14.20) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
132.01% | 218.12% | 636.97% | 633.46% | |
Selling, General and Administrative Expense of Revenue |
320.68% | 483.13% | 931.09% | 649.62% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
62.71% | 56.31% | 119.75% | 131.20% | |
Graham Net Nets |
0.18 | 0.29 | 0.18 | 0.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(31.63%) | (32.67%) | (38.10%) | (28.35%) | |
Free Cash Flow Yield |
(25.75%) | (29.43%) | (36.98%) | (22.34%) | |
Revenue per Share |
0.02 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.06) | (0.10) | (0.09) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.06) | (0.10) | (0.09) | (0.06) | |
Cash per Share |
0.20 | 0.33 | 0.20 | 0.27 | |
Shareholders Equity per Share |
0.19 | 0.30 | 0.15 | 0.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.19 | 0.30 | 0.15 | 0.22 | |
Free Cash Flow |
(2.94) | (3.71) | (3.02) | (2.27) | |
Working Capital |
8.93 | 11.80 | 5.93 | 9.10 | |
Capital Expenditures |
(0.07) | — | 0.00 | 0.00 | |
Net Current Asset Value |
8.32 | 11.02 | 5.22 | 7.85 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.08 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.42 | 0.26 | 0.09 | — | |
Average Payables |
0.77 | 1.04 | 0.69 | 0.78 | |
Average Assets |
12.56 | 14.99 | 8.11 | 10.62 | |
Average Common Equity |
9.81 | 12.21 | 4.95 | 7.57 |
Columns are period end dates